FDA accepts NDA for Miconazole Lauriad, a treatment for oropharyngeal candidiasis (OPC) - MPR
Links shared publicly online about this topic.
- 1,811total visits
FDA accepts NDA for Miconazole Lauriad, a treatment for oropharyngeal candidiasis (OPC) - MPR
empr.com —
View full resource at empr.com
Tags: Yeast Infection, Candidiasis, Vaginal Infection, Drug, Pharma, FDA, News
Most Recently Shared on August 19, 2009 at 11:02 pm By:
MPR News: FDA accepts NDA for Miconazole Lauriad, a treatment for oropharyngeal candidiasis (OPC): Stra.. http://bit.ly/3QczF3
U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa Pharmaceuticals
news-medical.net — “Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad((R)) mucoadhesive buccal tablets (MBT) to treat oropharyngeal candidiasis (OPC).” View full resource at news-medical.net
Most Recently Shared on August 19, 2009 at 2:12 pm By:
HIV/AIDS News: U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa.. http://ub0.cc/kN/11
Advertisement
